COMPARISON
Degarelix vs Triptorelin
5 attributes held for at least one of the two. 4 differ. Each value carries the register it came from and the date that register was read.
Answer
Degarelix is authorised or registered in 8 and Triptorelin in 10 of the 10 registers read. Degarelix: highest phase Phase 3 (7 phase 3 trials, 0 with posted results). Triptorelin: highest phase Phase 4 (after approval). 38 registered trials include both.
States no view on which is preferable, safer or more effective. Not medical advice.
| Degarelix | Triptorelin | |
|---|---|---|
| Registered trials differs | 187 clinicaltrials.gov · 2026-10-03 | 317 clinicaltrials.gov · 2026-10-03 |
| FDA label differs | FDA-approved: FIRMAGON openfda · 2026-10-03T17:23:44.062Z | FDA-approved: Trelstar openfda · 2026-10-03T17:23:44.062Z |
| EU authorisation | Authorised ema · 2026-10-03 | Authorised ema · 2026-08-31 |
| EU authorised on differs | 2009-02-17 ema · 2026-10-03 | Not checked no record of "authorisedOn" for triptorelin |
| ATC code differs | L02BX02 ema · 2026-10-03 | Not checked no record of "atcCode" for triptorelin |
SIDE EFFECTS
Most common side effects, each beside its own placebo
| Side effect | Degarelix | placebo | Triptorelin | placebo |
|---|---|---|---|---|
| Injection site erythema | 14.1% | 0.0% | - | - |
| Injection site pain | 8.4% | 0.0% | - | - |
| Injection site induration | 7.8% | 0.0% | - | - |
| Hypertension | 6.2% | 7.1% | - | - |
| Back pain | 4.9% | 9.2% | - | - |
| Prostatic specific antigen increased | 4.9% | 6.1% | - | - |
| Nasopharyngitis | 4.6% | 5.1% | - | - |
| Hot flush | 4.3% | 0.8% | - | - |
| Influenza | 4.2% | 5.1% | - | - |
| Headache | 2.9% | 5.1% | - | - |
Trial register Degarelix: 2 placebo-controlled trials; Triptorelin: 0. Each peptide is compared with placebo in its own trials, not with the other: a dash means the event is not in that peptide's top list. Degarelix side effects · Triptorelin side effects
LEGAL STATUS
Approval in each country read
| Country | Degarelix | Triptorelin | Register |
|---|---|---|---|
| United States | FDA-approved | FDA-approved | Regulator FDA |
| European Union | Authorised | Authorised | Regulator EMA |
| United Kingdom | Authorised | Authorised | Regulator MHRA |
| Canada | Authorised | Authorised | Regulator Health Canada |
| Australia | Registered | Registered | Regulator TGA |
| Switzerland | Authorised | Authorised | Regulator Swissmedic |
| Brazil | Registado | Registado | Regulator ANVISA |
| Serbia | Not on the register | Authorised | Regulator ALIMS |
| Singapore | Registered | Registered | Regulator HSA |
| Turkey | Not on the register | Ruhsatli | Regulator TITCK |
HEAD TO HEAD
38 registered trials include both
| 2023-509494-23-00 | DARIUS : A RANDOMIZED NON-COMPARATIVE PHASE II MULTICENTRIC TRIAL ON SHORT TERM DAROLUTAMIDE (ODM-201) CONCOMITANT TO RADIATION THERAPY FOR PATIENTS WITH INTERM Not stated · updated 2026-09-07 |
|---|---|
| NCT02005887 | TRial on the Endocrine Activity of Neoadjuvant Degarelix COMPLETED · updated 2026-09-02 |
| 2024-517285-41-00 | ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with pelvic lymph nodes me Not stated · updated 2026-08-21 |
| NCT04423211 | Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging RECRUITING · updated 2026-08-19 |
| NCT04513717 | Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatm ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT05050084 | Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a ACTIVE_NOT_RECRUITING · updated 2026-08-17 |
| NCT07751133 | Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer NOT_YET_RECRUITING · updated 2026-08-07 |
| NCT07455903 | Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT RECRUITING · updated 2026-08-06 |
| NCT06378866 | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy RECRUITING · updated 2026-07-20 |
| NCT02346253 | High-Dose Brachytherapy in Treating Patients With Prostate Cancer COMPLETED · updated 2026-07-02 |
| NCT06922318 | The COSMYC Trial (COmbined Suppression of MYC) RECRUITING · updated 2026-06-18 |
| NCT07477626 | Radiotherapy After Prostatectomy for Node Positive Prostate Cancer RECRUITING · updated 2026-06-16 |
| 2023-506817-23-01 | EORTC-2238-GUCG: Intermittent Androgen deprivation Therapy in the era of AR pathway inhibitors; a phase 3 pragmatic randomized trial (DE-ESCALATE) Not stated · updated 2026-06-08 |
| 2023-507482-26-00 | PEACE 8: Combination of darolutamide and stereotactic body radiation therapy in patients with castration resistant prostate cancer and oligometastases on functi Not stated · updated 2026-05-29 |
| NCT04787744 | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Can RECRUITING · updated 2026-04-08 |
| NCT06734130 | Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer ACTIVE_NOT_RECRUITING · updated 2026-04-01 |
| 2023-507970-42-00 | PSMAddition: An International Prospective Open-label, Randomized, Phase III Study comparing 177Lu-PSMA-617 in combination with Standard of Care, versus Standard Not stated · updated 2026-03-24 |
| NCT06282588 | Treatment of High-Risk Prostate Cancer Guided by Novel Diagnostic Radio- and Molecular Tracers RECRUITING · updated 2026-03-19 |
| NCT07142551 | Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response RECRUITING · updated 2026-03-11 |
| NCT00936390 | Radiation Therapy With or Without Androgen-Deprivation Therapy in Treating Patients With Prostate Cancer COMPLETED · updated 2026-03-06 |
The 20 most recently updated are listed.
Values reproduce public registers on the dates shown. This comparison states no view on which compound is preferable, safer or more effective. Not medical, legal or regulatory advice.
WEEKLY
Register Watch, weekly
New trials, approvals and enforcement actions. One email a week.